Abstract:Skull base disorders (SBDs) have gained attention within the medical community due to the rising incidence and complexity of treatment. SBD risk has been correlated with low socioeconomic status (SES), among other factors.[1] [2] Importantly, low SES is linked to reduced geographic accessibility to health care services,[3] including clinical trials, a disparity accentuated by the coronavirus disease 2019 (COVID-19) pandemic. To elucidate the concept of geographic accessibility within SBDs, we performed a retrospective trend analysis, evaluating geographic access to SBD clinical trials across the United States for a period of 20 years. The clinical trial data were obtained from the ClinicalTrials.gov Application Programming Interface (API) by using a comprehensive keyword search strategy related to SBDs. Next, we measured SBD population demographics from the Census.gov API. Lastly, we calculated distances between ZIP code population centers and clinical trial locations using the Haversine formula[4] and then assessed changes in accessibility over time starting from 2005 until 2024. We identified 18,750 SBD clinical trials, 12,044 of which were initiated before 2020 and 6,706 after. At least one clinical trial was hosted at 2,442 unique ZIP codes, with an average of 7.86 trials per each of these zip codes. Linear regression analysis demonstrated a slight increase in the average distance to the nearest clinical trial over time (slope = 1.87 km/year), with substantial increases from post-COVID, although this trend was not statistically significant ( p = 0.0739; [Fig. 1]). The population coverage at various distance thresholds over time was also evaluated ([Table 1]). When assessing population coverage before and after 2020, no significant reduction in accessibility postpandemic was found ( t -test statistic = 1.47, p = 0.205). However, the number of clinical trials decreased consistently from pre- to post-COVID, with 2,997 trials in 2019 and just 586 by 2023. While this reduction may reflect a disruption in research activities due to the pandemic, other factors may also have played a role, such as rising clinical demands on health care providers detracting from clinical trial initiation, shifts in research priorities, or decreased governmental or private funding for trials during this period. Year 10 miles 20 miles 30 miles 40 miles 50 miles 60 miles 70 miles 80 miles 90 miles 100 miles 2005 54.04 72.8 81.1 85.9 88.97 91.19 93.1 94.77 95.9 96.89 2006 53.24 71.48 79.56 84.7 88.11 90.65 92.81 94.24 95.59 96.41 2007 54.53 70.86 78.96 84.01 87.74 90.34 92.75 94.42 95.68 96.81 2008 63.85 78.88 85.62 89.78 92.52 94.55 95.7 96.72 97.46 97.97 2009 55.01 72.64 80.45 85.39 88.72 91.34 93.12 94.62 95.76 96.54 2010 53.62 71.29 79.64 84.58 88.2 90.77 92.93 95.11 96.98 98.07 2011 49.35 67.55 75.68 81.27 84.93 87.55 89.76 91.96 93.45 94.62 2012 51.32 68.34 76.17 81.86 85.69 88.58 90.96 92.68 94.25 95.7 2013 47.93 66.21 74.3 79.51 83.33 86.73 89.43 91.08 92.96 94.24 2014 67.97 82.59 88.85 92.78 94.96 96.56 97.44 98.08 98.58 98.83 2015 71.87 85.02 90.72 94.15 95.96 97.28 98.03 98.6 98.98 99.21 2016 56.26 73.92 81.07 86.48 89.85 92.24 94.06 95.31 96.15 96.79 2017 67.54 81.06 86.85 90.91 93.33 95.15 96.38 97.16 97.69 98.17 2018 51.84 68.88 76.54 80.96 84.23 86.82 89.11 90.93 92.83 94.33 2019 66.22 79.74 85.8 89.53 92.25 94.42 96.13 97.27 98.2 98.68 2020 70.7 82.97 88.76 92.43 94.73 96.2 97.24 97.91 98.49 98.97 2021 58.59 72.61 80.23 84.64 87.87 90.09 92.13 93.88 95.46 96.72 2022 44.39 60.61 68.57 73.37 77.34 80.46 82.8 84.77 86.93 89.35 2023 49.41 65.33 72.08 77.44 81.22 84.3 87.02 89.53 91.39 93.18 2024 33.23 48.45 56.74 61.86 66.56 70.29 73.96 78.11 81.01 83.79 The results are consistent with previous studies demonstrating a correlation between geographic accessibility and health care facility use.[5] The coverage analysis shows decreasing accessibility to trial sites, particularly within shorter distances (i.e., 10 and 20 miles), suggesting that these locations are becoming less accessible for a larger portion of the population. Additionally, the average distance to SBD clinical trials is increasing while the total number of such trials is decreasing with time, reflecting the fragility of the clinical trial infrastructure in the wake of the COVID-19 pandemic.[6] Although many of these trends did not reach statistical significance, they suggest the need for ongoing efforts to expand the geographic footprint of clinical trials and ultimately alleviate patient travel burdens. One of these efforts may include increased funding dedicated to SBD clinical trials from public sources, such as the National Institute of Health, which would provide greater resources to establish studies in underserved or rural areas. Another effort may be stronger collaborations with local health care institutions, which could facili -Abstract Truncated-

Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States

Geographic Proximity to Cardiovascular Clinical Trial Sites: A National Analysis in the United States

Geographic disparity in the distribution of cancer clinical trials in the United States and the associated factors

Disparities in gynecologic oncology clinical trial availability in the United States: A state-level analysis.

Diversity in Enrollment to Clinical Trials for Cataract Medicine and Surgery: A Meta-Analysis

The influence of socioeconomic status on individual attitudes and experience with clinical trials

Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time

Healthcare disparities are associated with eligibility and enrollment in clinical trials in Louisiana.

Running the enrollment numbers on ophthalmic clinical trials in the United States

Health disparities in ocular oncology

Disparities Between Clinical Trial Recruitment and Real-World Demographics in Macular Edema Secondary to Retinal Vein Occlusion

Socioeconomic Disparities in Glaucoma Severity at Initial Diagnosis: A Nationwide Electronic Health Record Cohort Analysis

Impact of Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation in Non-Hodgkin Lymphoma

Abstract 1309: Assessment of geographic and socioeconomic factors in primary brain tumor patient accrual to a natural history study

Ethnicity and Socioeconomic Disparities in Clinical Trial Participation for Ovarian Cancer: A Retrospective Observational Study in London

Factors influencing willingness to participate in ophthalmic clinical trials and strategies for effective recruitment

How Accessible are Clinical Trials for Skull Base Disorders within the United States?

Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US

Racial and Socioeconomic Differences in Eye Care Utilization among Medicare Beneficiaries with Glaucoma

Abstract A128: A novel approach to understanding disparities in cancer clinical trial enrollment

Mediators of racial and ethnic inequities in clinical trial participation among patients with cancer, 2011-2023